Salivary antibodies induced by the seven-valent PncCRM conjugate vaccine in the Finnish Otitis Media Vaccine Trial. (Q51996513)

19 April 2018

title

Salivary antibodies induced by the seven-valent PncCRM conjugate vaccine in the Finnish Otitis Media Vaccine Trial. (English)

1 reference

19 April 2018

0 references

4

Helena Käyhty

1 reference

19 April 2018

author name string

Anu Nurkka

1

1 reference

19 April 2018

Mika Lahdenkari

2

1 reference

19 April 2018

Arto Palmu

3

1 reference

19 April 2018

FinOM Study Group

5

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 December 2004

1 reference

19 April 2018

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

19 April 2018

volume

23

1 reference

19 April 2018

issue

3

1 reference

19 April 2018

page(s)

298-304

1 reference

19 April 2018

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conju

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzas type b conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Immunogenicity of pneumococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Evaluation of monoclonal antibodies with specificity for human IgA, IgA subclasses and allotypes and secretory component. Results of an IUIS/WHO collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Mucosal immune response in the ear, nose and throat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

The impact of conjugate vaccine on carriage of Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Conjugate vaccines and the carriage of Haemophilus influenzae type b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal capsular polysaccharides in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Subclass distribution of IgA antibodies in saliva and serum after immunization with Haemophilus influenzae type b conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

Antibody-enhanced pneumococcal adherence requires IgA1 protease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.009

10.1016/J.VACCINE.2004.06.009

7 January 2021

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018